Cisplatin Injection
Cisplatin Injection - Related Videos
04:04
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
0 Views •
Cited by 13 •
2017
The management of isolated recurrent lung cancer in a previously-irradiated field is challenging. Here, we describe an endobronchial ultrasound (EBUS)-guided cisplatin injection for the management of patients with localized lung cancer recurrence in a previously-radiated field.
07:47
Custom-designed Laser-based Heating Apparatus for Triggered Release of Cisplatin from Thermosensitive Liposomes with Magnetic Resonance Image Guidance
0 Views •
Cited by 17 •
2015
AN MRI-compatible custom-designed laser-based heating apparatus has been developed to provide local heating of subcutaneous tumors in order to activate release of agents from thermosensitive liposomes specifically at the tumor region.
13:25
Acute Kidney Injury Model Induced by Cisplatin in Adult Zebrafish
0 Views •
Cited by 10 •
2021
This protocol describes the procedures to induce Acute Kidney Injury (AKI) in adult zebrafish using cisplatin as a nephrotoxic agent. We detailed the steps to evaluate the reproducibility of the technique and two techniques to analyze inflammation and cell death in the renal tissue, flow cytometry and TUNEL, respectively.
04:20
Knockdown of FAM83A to Verify Its Role in Cervical Cancer Cell Growth and Cisplatin Sensitivity
0 Views •
2024
Here, we show the procedures for FAM83A knockdown; the assays to detect its effects on proliferation, migration, and invasion of cervical cancer cells; and the sensitization of these cells to cisplatin. This study provides a promising target gene for cervical cancer and a reference for further drug research.
08:28
Zebrafish Brain Ventricle Injection
0 Views •
Cited by 72 •
2009
After neural tube formation, the neuroepithelium constricts and folds while the tube fills with embryonic cerebrospinal fluid (eCSF) to form the embryonic brain ventricles. We developed this ventricle injection technique to better visualize the fluid filled space in contrast to the neuroepithelial shape in a live embryo.
FAQs
Cisplatin's antitumor effect depends on DNA crosslinks rather than a simple temporary interruption of cell activity. Its platinum center creates covalent links between DNA bases, either within one strand or between two strands. These lesions distort the helix, making the genetic material difficult to copy or read. The resulting replication and transcription disruption contributes to tumor-cell injury.
Cisplatin-related DNA injury can also affect healthy cells because the molecular damage is not exclusive to malignant tissue. Rapidly dividing tumor cells may be especially vulnerable, but normal tissues can sustain injury as well. This lack of absolute selectivity helps explain why treatment planning includes toxicity surveillance rather than focusing only on tumor response.
When cisplatin-induced lesions interfere with DNA replication and transcription, affected cells may enter cell-cycle arrest, stopping or slowing their progression through division. Sufficient or persistent damage can then activate apoptosis, a programmed form of cell death. This sequence links the initial chemical modification of DNA with the loss of viable malignant cells.
Cisplatin injection is given intravenously as part of a planned chemotherapy regimen. Clinical use requires a defined dose and monitoring for treatment-related toxicity. The medicine may be administered alone or combined with other treatments, depending on the regimen being used. These elements connect drug delivery with safe, clinically supervised cancer care.
Its documented clinical applications include testicular, ovarian, bladder, lung, and head and neck cancers. Cisplatin may serve as a single medicine or as one component of a combination regimen. This broad use reflects the relevance of DNA-damaging chemotherapy across several tumor types, while the specific treatment plan still requires clinical dosing and safety monitoring.
Monitoring commonly focuses on nephrotoxicity, ototoxicity, neurotoxicity, and myelosuppression. These terms describe potential injury to the kidneys, hearing-related structures, the nervous system, and bone-marrow function, respectively. Because healthy tissues may also be affected, tracking these toxicities is an essential part of clinical management and helps place the anticancer benefit in the context of treatment safety.